1,721,090 research outputs found
Iodized oil pleural effusion in a patient previously treated with transarterial chemoembolization for hepatocellular carcinoma
No full textTransarterial chemoembolization (TACE) is a nonsurgical therapeutic option for the control of hepatocellular carcinoma (HCC) in patients with cirrhosis. Although less invasive than surgical approaches, this procedure can have severe side effects, with both local and extrahepatic complications, mostly related to treatment-induced ischemic damage. Here, we describe the case of a cirrhotic female patient affected by multinodular HCC, who presented with sudden onset dyspnea and chest pain. After a thorough follow-up, her condition was found to be due to iodinized oil pleural effusion following diaphragm rupture by a fistula. This had developed from a sterile abscess formed on the site of a previously performed TACE. We discuss the differential diagnosis and the management of this case, which, to our knowledge, has never been described as a late side effect of TACE. © 2010 American College of Chest Physicians
Applications, challenges and future directions of artificial intelligence in cardio-oncology
No full textBackground: The management of cardiotoxicity related to cancer therapies has emerged as a significant clinical challenge, prompting the rapid growth of cardio-oncology. As cancer treatments become more complex, there is an increasing need to enhance diagnostic and therapeutic strategies for managing their cardiovascular side effects. Objective: This review investigates the potential of artificial intelligence (AI) to revolutionize cardio-oncology by integrating diverse data sources to address the challenges of cardiotoxicity management. Methods: We explore applications of AI in cardio-oncology, focusing on its ability to leverage multiple data sources, including electronic health records, electrocardiograms, imaging modalities, wearable sensors, and circulating serum biomarkers. Results: AI has demonstrated significant potential in improving risk stratification and longitudinal monitoring of cardiotoxicity. By optimizing the use of electrocardiograms, non-invasive imaging, and circulating biomarkers, AI facilitates earlier detection, better prediction of outcomes, and more personalized therapeutic interventions. These advancements are poised to enhance patient outcomes and streamline clinical decision-making. Conclusions: AI represents a transformative opportunity in cardio-oncology by advancing diagnostic and therapeutic capabilities. However, successful implementation requires addressing practical challenges such as data integration, model interpretability, and clinician training. Continued collaboration between clinicians and AI developers will be essential to fully integrate AI into routine clinical workflows
Purpura as the initial presentation for small-cell lung cancer
No full textBACKGROUND: Causes of thrombocytopenia (TP) in patients affected by small-cell lung cancer (SCLC) include myelophtysis, immunomediated TP, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, drug-related TP, and amegakaryocytic TP. However, isolated TP is an exceedingly rare presentation of SCLC.
CASE REPORT: Here, we report on a 78-year-old Caucasian man with SCLC whose only clinic manifestation at the beginning of his clinical course was a diffuse purpuric rash, indeed due to severe isolated TP. A thorough clinical workup led us to the diagnosis of secondary amegakaryocytic TP, which resolved after chemotherapy.
CONCLUSION: To the best of our knowledge, this is the first described case of SCLC presenting with amegakaryocytic TP. SCLC should be considered in the differential diagnosis of isolated TP, as should rare triggering conditions like amegakaryocytic TP when evaluating therapeutic opportunities in thrombocytopenic patients
DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.
No full text
Transcriptomic and genomic features of invasive lobular breast cancer
No full textAccounting for 10–15% of all breast neoplasms, invasive lobular breast cancer (ILC) is the second most common histological subtype of breast cancer after invasive ductal breast cancer (IDC). Understanding ILC biology, which differs from IDC in terms of clinical presentation, treatment response, relapse timing and patterns, is essential in order to adopt novel, disease-specific management strategies. While the contribution of the histological subtypes to tumour biology has been poorly investigated and acknowledged in the past, recently several major, independent efforts have led to the assembly and molecular characterization of well-annotated ILC case sets. In this review, we provide a critical overview of the literature exploring ILC, through comprehensive and multiomic methods. The first part specifically focuses on ILC transcriptomic features by reviewing the intrinsic molecular subtypes, the application of gene expression scores for the prediction of recurrence, and the identification of gene expression subtypes. The second part describes the main research efforts that lead to the identification of the genomic landscape of ILC, with a special focus to findings that differentiate ILC from IDC and carry potential clinical relevance.SCOPUS: re.jinfo:eu-repo/semantics/publishe
Identification of a Predominant Co-Regulation among Kinetochore Genes, Prospective Regulatory Elements, and Association with Genomic Instability
No full text
OMEGA (Offline Mutation Easy Genetic Annotator), a software analysis pipeline designed for thorough and easy annotation of NGS output
No full text- …
